Abstract
In this present work, 5-chloro-3-(substituted-benzylidene)indolin-2-one and 1-benzyl-5-chloro-3-(substitutedbenzylidene) indolin-2-one derivatives were synthesized and evaluated for their inhibitory activity against Src Family Kinases (SFKs) such as Fyn, Lyn and Hck. 5-Chloro-3-(substituted)indolin-2-ones (3a - 6a) and 1-benzyl-5-chloro-3- (substituted-benzylidene)indolin-2-ones (3b - 6b) were prepared by condensation of 5-chloro oxindole and 1-benzyl-5- chloro oxindole with the equivalent amount of aldehydes in EtOH in the presence of piperidine. Among all compounds, only 4a, 5b and 6b were found slightly active against Fyn with 13 - 16% inhibitions at 0.1 and 0.01 mM concentrations. Compounds did not exhibit any inhibitory potency against Lyn and Hck. Docking study of compounds was performed to evaluate receptor-binding properties of compounds and the results showed that the most active compound 6b binds into the active site of Fyn, which has similar binding mode with potent inhibitor PP2.
Keywords: Oxindole derivatives, Inhibition of SFKs, Synthesis, Selectivity, Docking, Activity.
Letters in Drug Design & Discovery
Title:Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Volume: 10 Issue: 8
Author(s): Zühal Kilic-Kurt, Arzu Onay-Besikci and Sureyya Olgen
Affiliation:
Keywords: Oxindole derivatives, Inhibition of SFKs, Synthesis, Selectivity, Docking, Activity.
Abstract: In this present work, 5-chloro-3-(substituted-benzylidene)indolin-2-one and 1-benzyl-5-chloro-3-(substitutedbenzylidene) indolin-2-one derivatives were synthesized and evaluated for their inhibitory activity against Src Family Kinases (SFKs) such as Fyn, Lyn and Hck. 5-Chloro-3-(substituted)indolin-2-ones (3a - 6a) and 1-benzyl-5-chloro-3- (substituted-benzylidene)indolin-2-ones (3b - 6b) were prepared by condensation of 5-chloro oxindole and 1-benzyl-5- chloro oxindole with the equivalent amount of aldehydes in EtOH in the presence of piperidine. Among all compounds, only 4a, 5b and 6b were found slightly active against Fyn with 13 - 16% inhibitions at 0.1 and 0.01 mM concentrations. Compounds did not exhibit any inhibitory potency against Lyn and Hck. Docking study of compounds was performed to evaluate receptor-binding properties of compounds and the results showed that the most active compound 6b binds into the active site of Fyn, which has similar binding mode with potent inhibitor PP2.
Export Options
About this article
Cite this article as:
Kilic-Kurt Zühal, Onay-Besikci Arzu and Olgen Sureyya, Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases, Letters in Drug Design & Discovery 2013; 10 (8) . https://dx.doi.org/10.2174/15701808113109070023
DOI https://dx.doi.org/10.2174/15701808113109070023 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Epigenetic Mechanisms Underlying Diet-Sourced Compounds in the Prevention and Treatment of Gastrointestinal Cancer
Anti-Cancer Agents in Medicinal Chemistry Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Patent Selections:
Recent Patents on Medical Imaging The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry 4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors - An Update
Medicinal Chemistry Reviews - Online (Discontinued) Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Taming Oncogenic Signaling at Protein Interfaces: Challenges and Opportunities
Current Topics in Medicinal Chemistry Immediate Early Proto-Oncoproteins and Membranes: Not Just An Innocent Liaison
Current Protein & Peptide Science Molecular Surgery with Auger Electron-Emitting Radiopharmaceuticals
Current Radiopharmaceuticals Oncogenic Signaling Pathways Activated by RON Receptor Tyrosine Kinase
Current Cancer Drug Targets Erythropoietin in Cancer: An Update
Current Molecular Medicine A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery In Silico Approach to Finding New Active Compounds from Histone Deacetylase (HDAC) Family
Current Pharmaceutical Design Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design IDO and Clinical Conditions Associated with Depressive Symptoms
Current Drug Metabolism Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews In Silico Bioisosteric Replacements of hnRNP K Ligands as Anticancer Lead Compounds
Current Physical Chemistry The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design